http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease
-
ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA
-
Regeneron (REGN), Sanofi (SNY) Receive Marketing Approval for Praluent in Japan
-
Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
-
CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX
-
VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
Regeneron (REGN), Sanofi (SNY) Announce LIBERTY AD CHRONOS Met Primary Endpoint
-
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe A
-
ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016
-
Top 10 News for 5/23 - 5/27: Computer Sciences to Acquire Key Enterprise Asset; Bayer Makes Run at Monsanto; Twitter has 'Character' Change
-
ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE
-
ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION
-
ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX TO RECEIVE AN EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY
-
Announcing the 2016 American Academy of Neurology Research Program Recipients
-
Pre-Open Stock Movers 04/13: (RPRX) (ACUR) (MDVN) Higher; (CLVS) (VRX) (S) Lower (more...)
-
Regeneron (REGN), Sanofi (SNY)Announce Two Dupilumab Phase 3s Met Primary Endpoint in Atopic Dermatitis
-
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
-
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
Amgen (AMGN) Comments Following Repatha Patent Win
-
Regeneron (REGN) and Sanofi Confirm Negative Praluent Ruling, 'Strongly Disagree' with Verdict (AMGN)
-
Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
Regeneron (REGN), Sanofi (SNY) Announce Sarilumab vs. Adalimumab Phase 3 Met Primary Endpoint in Active RA
-
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
-
Bioengineered Organ Implant Developer HART Names Accomplished Biotechnology Executive Dr. Blaine McKee to its Board
-
Sanofi Pasteur (SNY) and Merck (MRK) to End Joint Vaccines Operations in Europe
-
Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strateg
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
Omicia Announces Appointment of Matt Tindall as Chief Executive Officer
-
HART Appoints Laura Mondano as Vice President of Regulatory Affairs To Lead HART's 2016 IND Submission For its Bioengineered Organ Implant Solutions
-
ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS
-
Bioventus Enters Into Agreement with IBSA for Rights to GELSYN-3™
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
-
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
-
ABLYNX TO RECEIVE EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX
-
Regeneron (REGN), Sanofi (SNY) Announce U.S. FDA Acceptance of Sarilumab BLA
-
Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
-
ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS
